IFF's Q2 2026 earnings discussion highlights post-divestiture Capex guidance of about 5-6% of sales, with a tilt toward 6% over the next 1–2 years as high-return initiatives advance. Management ties reinvestment, including R&D at roughly 9% of sales, to growth and margin expansion while prioritizing organic scaling and bolt-ons for Remainco.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What did management say about Capex and reinvestment post-divestiture?
Management guided Capex (blended across the portfolio) at ~5% to 6% of sales as part of the post–Food Ingredients divestiture investment thesis. Capex was explicitly discussed as a targeted run-rate, with management noting that H&B runs at a higher rate and that the blended result of 5% to 6% “makes a lot of sense” for what IFF is targeting. 1
Management also said that, over the next 1–2 years, they expect Capex to be at the upper end of that 5% to 6% range (closer to 6%) because they have “critical initiatives” that are described as high-return initiatives to be executed going forward. 2
Management emphasized reinvestment as part of the Remainco strategy, explicitly tying reinvestment and innovation to the “circle” where investments improve growth and support margin expansion while continuing to reinvest. 1
On reinvestment intensity via R&D, management said R&D is already being increased and will remain a key pillar for competing (including in China). Specifically, management stated R&D was ~7% of sales prior to the last 2.5 years and is ~9% of sales today, and they intend to continue to increase R&D spend as sales grow, while also considering increasing R&D further if it is value-creating. 3
(While R&D is not Capex, it is directly relevant to “reinvestment” and management’s stated priority to fund innovation post-divestiture.)
In response to investor questions about how the divestiture affects Capex, management framed the separation as part of broader free cash flow improvement and reinvestment planning, including the pivot toward reinvestment and innovation. 4
Additionally, management discussed that free cash flow is expected to be higher in full-year 2026 versus 2025, and that this includes working capital headwinds around the Food Ingredients stand. 5 While this is not a direct Capex number beyond the 5–6% guidance, it provides the “capital allocation capacity” context for reinvestment after divestiture. 5
Management also clarified that, after Food Ingredients, they viewed the portfolio actions as largely completed and shifted emphasis toward scaling the remaining businesses organically and via bolt-ons—i.e., reinvestment rather than further large divestitures. Management stated they expect to have “no significant divestitures left to do” and that it’s “all about scaling organically and through bolt-ons” across the three high-innovation businesses (Scent, Taste, H&B). 6
Management connected the higher near-term Capex to execution of “critical initiatives” that are characterized as high-return. This aligns with their broader statement that stranded costs from the divestiture are temporary and that they expect to continue transformation and margin improvement while executing the remediation plan. 2 7
In particular, they described stranded costs of about $100 million expected to remain temporarily post-close, with a plan to eliminate ~2/3 within the first 12 months and the remainder in the second full year post-close—supporting their longer-term margin enhancement narrative that reinvestment funding is meant to reinforce. 7 8
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Post-divestiture, IFF plans Capex around 5-6% of sales, with the upper end near 6% in the next 1-2 years to fund high-return initiatives, while keeping reinvestment and R&D at 8-9% of sales to support growth. Near-term cash-flow timing headwinds from the divestiture are expected, but full-year 2026 free cash flow should exceed 2025.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF outlines a Capex target of 5-6% of sales and an emphasis on sustaining reinvestment, notably in innovation. Management ties R&D at 8-9% of sales to a growth-and-margin expansion cycle, while acknowledging temporary stranded costs and working-capital headwinds from the separation.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF outlines a disciplined reinvestment strategy after divestiture, targeting 5-6% of sales in capex (closer to 6% in 1-2 years) and sustaining R&D around 8-9%, with 2026 free cash flow expected to rise despite near-term working-capital headwinds.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF outlines a reinvestment-led transformation plan. Capex is targeted at roughly 5–6% of sales, with a tilt toward the 6% range in the next 1–2 years to fund high-return, innovation-driven initiatives. R&D sits around 9% of sales. Near-term cash flow effects are driven more by working capital than capex policy, and the portfolio is viewed as set after the Food Ingredients divestiture.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF signals a 5-6% capex run-rate (likely near 6% in the next 1-2 years) alongside 8-9% of sales in R&D, tying reinvestment to Remainco growth and margin expansion. Management also expects cash-flow improvements over time as the divestiture optimizes the capital mix.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF outlines a disciplined post-divestiture reinvestment plan, targeting CapEx at 5-6% of sales and R&D at 8-9%, to differentiate the business and drive margin expansion. Despite near-term working capital headwinds, management expects 2026 free cash flow to exceed 2025, enabling continued reinvestment.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF signals a Capex target of 5-6% of sales, with near-term leaning toward ~6% to fund high-return initiatives. Reinvestment is anchored in R&D/innovation for the Remainco, with R&D running around 8-9% of sales and potential increases as sales grow.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF outlines post-divestiture Capex targets of roughly 5-6% of sales, with near-term guidance near the upper end to fund high-return initiatives, while prioritizing R&D reinvestment to support the Remainco growth and margin expansion. The discussion also covers stranded costs, cash-flow framing, and near-term working-capital headwinds tied to the divestiture.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Post-divestiture, IFF signals a disciplined capital allocation plan focused on a 5%-6% Capex target, with a near-term tilt toward 6%. It also emphasizes sustained R&D investment (about 8%-9% of sales, now around 9%) to drive growth and margin expansion.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi